Navigation Links
/R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/
Date:9/2/2008

gene amplification in their tumours (metastatic or primary) in order to qualify for the trial.

The primary objectives of the Phase 2 trial are to determine the objective response rate of REOLYSIN(R) in combination with paclitaxel and carboplatin in patients with metastatic or recurrent NSCLC with K-RAS or EGFR-activated tumours, and to measure progression-free survival at 6 months. The secondary objectives are to determine the median survival and duration of progression-free survival in patients, and to evaluate the safety and tolerability of REOLYSIN(R) in combination with paclitaxel and carboplatin in this patient population.

REOLYSIN(R) preferentially replicates in cancer cells that have an activated RAS pathway. Approximately two thirds of all cancers have an activated RAS pathway, including most metastatic disease. A large number of mutations, including mutations in EGFR, Her2 or K-RAS along the RAS pathway lead to RAS pathway activation.

Recent clinical studies in NSCLC with EGFR-based therapies have shown that patients with mutations or overexpression of EGFR, which are commonly found in NSCLC, derive clinical benefit from these therapies. An agent such as REOLYSIN(R) that selectively replicates in cancers with an activated RAS pathway resulting from EGFR mutations or overexpression may show similar benefit. However, patients with mutant K-RAS, or up to 20% of the more than 180,000 patients diagnosed every year in the U.S. with NSCLC, do not derive benefit from EGFR-based therapies. The introduction of screening for K-RAS mutations, and the exclusion of K-RAS mutated patients will lead to higher response rates in EGFR-mutated or overexpressed patients treated with EGFR-based therapies. This excluded patient group is therefore prescreened for RAS pathway activation resulting from mutations in K-RAS, and an agent such as REOLYSIN(R) may be indicated for this patient group. This study targets patients with either EGFR-activated tumours or K
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
2. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
3. Oncolytics Biotech Inc. Announces 2008 Second Quarter Results
4. Oncolytics Biotech Inc. Treats 200th Cancer Patient in Clinical Studies with REOLYSIN(R)
5. Oncolytics Biotech Inc. Announces U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
6. Oncolytics Biotech Inc. to Present at BIO 2008 International Convention
7. Oncolytics Biotech Inc. Announces Start of Enrolment in Phase 1/2 Ovarian Cancer Clinical Trial with REOLYSIN(R)
8. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
9. Oncolytics Biotech Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting
10. Oncolytics Biotech Inc. Collaborators to Present Reovirus Research at ASGT Meeting
11. Oncolytics Biotech Inc. Announces Issuance of 9th Canadian Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Hussey Copper , a leader in copper manufacturing ... Gilmour Academy Ice Arena,s conversion of more than 200 ... surface to help protect against bacteria.  MD-Cu 29 ... greater than 99.9% of MRSA, E-coli and other bacteria ... , Innovative Gilmour Academy prepares children ...
(Date:9/17/2014)... , 17 de septiembre de 2014 /PRNewswire/ ... principal proveedor mundial de soluciones logísticas avanzadas ... de la vida, anunció hoy la contratación ... global con sede en Rótterdam, Países Bajos, ... clientes Europa en rápido crecimiento. Según los ...
(Date:9/17/2014)... 17, 2014 The Pistoia Alliance, ... lowering the barriers to innovation in life sciences ... of Carmen Nitsche as Executive Director Business Development ... its global reach. , Carmen joins the Pistoia ... Corporate Development. At Accelrys, she managed various life ...
(Date:9/16/2014)... SAN DIEGO , Sept. 16, 2014  Biocom, ... life science community, recognizes the 9 th ... to the value of IT technologies in improving our ... California is one of the world,s most ... from EHRs to mobile health applications to genomic testing ...
Breaking Biology Technology:Innovative Gilmour Academy Ice Arena changes more than 200 fixtures to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 2Innovative Gilmour Academy Ice Arena changes more than 200 fixtures to Hussey Copper's MD-Cu29 antimicrobial copper to help protect against bacteria 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 2Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 3Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 4Cryoport contrata a Broekman Group para mejorar su apoyo operativo y logístico en Europa 5Pistoia Alliance Expands Business Development with Appointment of Carmen Nitsche 2Biocom Recognizes National Health IT Week 2
... SAN DIEGO, July 28, 2011 Gen-Probe Incorporated (NASDAQ: ... quarter of 2011, with total revenues of $135.9 million and ... "Gen-Probe posted record sales of APTIMA women,s health products in ... blood screening revenue to decline compared to strong sales a ...
... Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced ... the second quarter of 2011, the Company reported net income of ... of $5.2 million, or $0.09 loss per share, for the same ... the Company reported net income of $4.9 million, or $0.09 per ...
... ITMN ) today announced that it will release its ... A live conference call and webcast will be hosted by ... discuss business highlights and financial results for the second quarter ... the live teleconference, dial 888-567-5125 (U.S.) or 706-643-9223 (international), conference ...
Cached Biology Technology:Gen-Probe Reports Financial Results for the Second Quarter of 2011 2Gen-Probe Reports Financial Results for the Second Quarter of 2011 3Gen-Probe Reports Financial Results for the Second Quarter of 2011 4Gen-Probe Reports Financial Results for the Second Quarter of 2011 5Gen-Probe Reports Financial Results for the Second Quarter of 2011 6Gen-Probe Reports Financial Results for the Second Quarter of 2011 7Gen-Probe Reports Financial Results for the Second Quarter of 2011 8Gen-Probe Reports Financial Results for the Second Quarter of 2011 9Gen-Probe Reports Financial Results for the Second Quarter of 2011 10Gen-Probe Reports Financial Results for the Second Quarter of 2011 11Gen-Probe Reports Financial Results for the Second Quarter of 2011 12Gen-Probe Reports Financial Results for the Second Quarter of 2011 13Gen-Probe Reports Financial Results for the Second Quarter of 2011 14Neurocrine Biosciences Reports Second Quarter 2011 Results 2Neurocrine Biosciences Reports Second Quarter 2011 Results 3Neurocrine Biosciences Reports Second Quarter 2011 Results 4Neurocrine Biosciences Reports Second Quarter 2011 Results 5Neurocrine Biosciences Reports Second Quarter 2011 Results 6Neurocrine Biosciences Reports Second Quarter 2011 Results 7InterMune to Release Second Quarter Financial Results on August 4 2
(Date:9/16/2014)... severe maternal morbidity amongst women in Australia is ... study published today (17 September) in BJOG: ... , Australians generally enjoy high standards of living; ... exist, in particular between indigenous and non indigenous ... the independent impact of socioeconomic position on severe ...
(Date:9/16/2014)... 36 Pit Fire began on September 13, 2014. The ... It is currently over 2,300 acres in size and is ... 36 Pit Fire was calm Monday night due to higher ... an anchor point and beginning to construct a fireline on ... following resources are working on the fire: , 7 20-person ...
(Date:9/16/2014)... the dinosaurs 66 million years ago decimated the evergreens ... than their deciduous peers, according to a study led ... journal PLOS Biology . , Applying biomechanical ... leaves of angiosperms flowering plants excluding conifers ... of a diverse plant community thriving during a 2.2 ...
Breaking Biology News(10 mins):New study examines the impact of socioeconomic position & maternal morbidity in Australia 2New study examines the impact of socioeconomic position & maternal morbidity in Australia 3Meteorite that doomed dinosaurs remade forests 2Meteorite that doomed dinosaurs remade forests 3Meteorite that doomed dinosaurs remade forests 4
... Biobanks are repositories for tissue samples, usually in ... from surgical procedures. These samples are collected and used ... linked to personal health information regarding the sample donor. ... researchers who want to use them face important questions ...
... The Life Sciences Discovery Fund (LSDF) today announced awards ... therapies and key resources for medical researchers and health-care ... the three programs. The programs will be led ... across the state. Dr. David Flum will work with ...
... MADISON, WI, JUNE 28, 2011 -- The ... provides information needed to sustainably manage agroforestry systems. ... increase yields and also reduce financial and environmental ... that allows for site-specific evaluation of nutrient-production imbalances ...
Cached Biology News:Public prefers limited informed consent process for biobanks 2Public prefers limited informed consent process for biobanks 3Life Sciences Discovery Fund helps launch 3 programs to advance health research and development 2Analyzing agroforestry management 2
... MKK6 (phospho S207) ( Abpromise ... Antigen: Synthetic phosphopeptide derived ... site of Serine 207 (V-D-S P ... ID: 5608 ...
Rabbit polyclonal to Reptin/TIP49B/RUVB2 ( Abpromise for all tested applications). Antigen: Synthetic peptide (Human) Entrez Gene ID: 10856 Swiss Protein ID: Q6FIB9...
Mouse monoclonal [1Q17] to TGE Virus peplomer ( Abpromise for all tested applications)....
Goat polyclonal to ORC2L ( Abpromise for all tested applications). entrezGeneID: 4999 SwissProtID: Q13416...
Biology Products: